v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
May 31, 2026
May 31, 2025
May 31, 2026
May 31, 2025
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)        
Revenue $ 0 $ 174,000 $ 20,000 $ 531,923
Cost of goods sold 0 0 0 2,720
Gross profit 0 174,000 20,000 529,203
Operating expenses        
Research and development 970,834 2,717,501 2,117,562 6,356,637
General and administrative 1,022,970 1,206,920 2,921,776 3,364,706
Total operating expenses 1,993,804 3,924,421 5,039,338 9,721,343
Loss from operations (1,993,804) (3,750,421) (5,019,338) (9,192,140)
Other income (loss)        
Interest income 837 190 2,618 201
Unrealized loss on marketable securities 0 (40,375) (22,093) (22,267)
Total other income (loss) 837 (40,185) (19,475) (22,066)
Net loss before income taxes (1,992,967) (3,790,606) (5,038,813) (9,214,206)
Income taxes 14 0 4,403 0
Net loss (1,992,981) (3,790,606) (5,043,216) (9,214,206)
Less: Net loss attributable to non-controlling interest (1,779) (1,514) (7,028) (8,203)
Net loss attributable to Lexaria shareholders (1,991,202) (3,789,092) (5,036,188) (9,206,003)
Other comprehensive income        
Foreign currency translation adjustment 8,971 37,173 23,862 (61,257)
Total comprehensive loss $ (1,982,231) $ (3,751,919) $ (5,012,326) $ (9,267,260)
Basic and diluted loss per share $ (0.08) $ (0.21) $ (0.21) $ (0.53)
Weighted average number of common shares outstanding        
Basic and diluted 24,805,924 18,298,309 23,543,278 17,472,844